Danna nan don nuna banners ɗin ku akan wannan shafin kuma ku biya kawai don nasara

Labaran Waya

Sabuwar takardar izinin magani don cutar Parkinson

Written by edita

BioArctic AB (publ) ta sanar a yau cewa Ofishin Lamuni da Alamar kasuwanci ta Amurka (USPTO) ta ba da sabon haƙƙin mallaka na sinadari na magani don rigakafin ABBV-0805, wanda BioArctic ya ƙirƙira a matsayin yuwuwar maganin cutar Parkinson. Haɗin gwiwar zai fara aiki a ranar 24 ga Mayu, 2022, kuma zai ƙare a cikin 2041, tare da yuwuwar ƙara wa'adin ikon mallaka har zuwa 2046.

Abubuwan da aka ba da izini (US patent no. 11,339,212) yana mai da hankali kan antibody monoclonal ABBV-0805, wanda ke ɗaure da kuma kawar da nau'ikan tarawar cututtukan cututtukan da ake kira oligomers da protofibrils yayin da ke kare nau'in monomer physiological na alpha-synuclein. Manufar ita ce a samar da maganin da ke dakatar da ci gaban cutar Parkinson.

A Majalisar Kasa da Kasa ta Cutar Parkinson da Cututtukan motsi (MDS) a cikin Satumba 2021, sakamakon da aka gabatar daga binciken Phase 1 tare da ABBV-0805 sun goyi bayan ci gaba da haɓaka rigakafin rigakafi a cikin Mataki na 2 tare da allurai sau ɗaya kowane wata.

"Mun yi farin ciki da cewa Ofishin Lamuni da Kasuwancin Amurka ya ba da wannan sabon haƙƙin mallaka na ABBV-0805, wanda ke ba da kariya ta haƙƙin mallaka na dogon lokaci. Shawarar ita ce ƙara tabbatar da sabon yanayin binciken BioArctic kuma yana ƙarfafa kariyar yuwuwar maganin cutar Parkinson nan gaba a kasuwannin Amurka,” in ji Gunilla Osswald, Shugaba, BioArctic.

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...